Dong-A ST Receives EC Approval for Imuldosa (Biosimilar, Stelara)
Shots:
- Dong-A ST received EC approval for Imuldosa (DMB-3115), a biosimilar of Janssen's Stelara (Ustekinumab), following CHMP’s positive opinion & FDA's approval
- Imuldosa, initially developed by Dong-A Socio Holdings & Meiji Seika Pharma, & was transferred to Dong-A ST in 2020 for global development and commercialization. In 2021, it was out-licensed to Intas Pharmaceuticals for launch through subsidiaries, incl. Accord Biopharma (US) and Accord Healthcare (Europe, UK, Canada)
- Ustekinumab is a fully human anti-IL-12/IL-23 mAb indicated for the treatment of plaque psoriasis, psoriatic arthritis, & Crohn’s disease
Ref: Dong-A ST | Image: Dong-A ST
Related News:- Dong-A ST Receives the CHMP’s Positive Opinion for Imuldosa (Biosimilar, Stelara)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
